Skip to main content
Voyageur Pharmaceuticals Ltd. logo

Voyageur Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · VM ISIN · CA92918C1014 TSXV Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2023-03-30 Regulatory Filings
Country CA Canada
Listing TSXV VM

About Voyageur Pharmaceuticals Ltd.

https://voyageurpharmaceuticals.ca/

Voyageur Pharmaceuticals Ltd. develops and supplies contrast media products for medical imaging, including CT scans and fluoroscopy. The company operates using a vertically integrated "Earth to Bottle" strategy, controlling the entire supply chain from raw mineral acquisition to finished pharmaceutical product. Voyageur owns a significant, high-purity barium sulfate resource, positioning it as a secure and sustainable supplier of pharmaceutical-grade barium sulfate, the active ingredient in its commercialized contrast agents (e.g., SmoothX® and SmoothHD® series). This vertical control aims to ensure supply security and cost competitiveness, primarily targeting the North American market. The company is also actively developing iodine-based contrast media and V-Gas® Effervescent Granules to expand its portfolio of diagnostic imaging solutions.

Recent filings

Filing Released Lang Actions
52-109FV1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV1 Certification of Annual Filings Venture Issuer Basic Certificate signed by the CFO. It certifies the review and fair presentation of annual filings including the AIF, annual financial statements, and annual MD&A for the financial year ended November 30, 2022. The document is a certification letter and does not contain actual financial data or the full annual report itself. It explicitly states it is a certification and includes disclaimers about controls and procedures. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than the actual Annual Report (10-K) or other financial reports. The document length is short (3131 characters), consistent with a certification letter rather than a full report. Therefore, the correct classification is Regulatory Filings (RNS).
2023-03-30 English
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV1 Certification of Annual Filings by the CEO of Voyageur Pharmaceuticals Ltd. It certifies the review and fair presentation of the annual filings including the AIF, annual financial statements, and annual MD&A for the financial year ended November 30, 2022. The document is a certification letter and does not contain actual financial data or the full annual report itself. It explicitly states it is a certification under National Instrument 52-109 for venture issuers, which is a regulatory filing requirement. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than the actual annual report (10-K) or management discussion and analysis (MDA). The document length is short (3111 characters) and it is a standalone certification, not the full report or announcement of a report publication. Therefore, the correct classification is Regulatory Filings (RNS).
2023-03-30 English
Annual MD&A - English.pdf
Management Reports Classification · 100% confidence The document is titled 'Management's Discussion & Analysis for the Year Ended November 30, 2022' and contains detailed analysis of the company's financial position, business strategy, operational highlights, and forward-looking statements. It references the fiscal year ended November 30, 2022, and discusses financial activities such as private placements and capital raising. The content is consistent with a Management Discussion & Analysis (MD&A) report, which is typically classified under Management Reports (MDA). The document is substantive and contains detailed financial and operational information, not merely an announcement or certification. Therefore, the appropriate classification is MDA.
2023-03-30 English
Audited annual financial statements – English.pdf
Annual Report Classification · 100% confidence The document is titled 'Consolidated Financial Statements for the years ended November 30, 2022 and 2021' for Voyageur Pharmaceuticals Ltd. It includes an Independent Auditors' Report, consolidated statements of financial position, comprehensive loss, changes in equity, cash flows, and notes to the financial statements. The presence of detailed financial statements and notes, along with the auditor's opinion, indicates this is a full annual financial report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2022
2023-03-30 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 13-501F1 related to participation fees for reporting issuers, submitted to the Alberta Securities Commission. It includes a management certification by the CFO, market value calculations for equity securities over specified trading periods, and fee calculations. The document is primarily a regulatory filing with certification and financial data related to compliance fees, not a full financial report or earnings release. It is also relatively short (4459 characters) and contains a certification statement. Therefore, it fits best under Regulatory Filings (RNS) as it does not represent a full annual or interim report, earnings release, or other specific report types.
2023-03-30 English
News release - English.pdf
Regulatory Filings
2023-02-14 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.